Department of Pediatrics and Pediatric Neurology, Georg August University, Faculty of Medicine, Robert-Koch-Strasse 40, D-37075 Göttingen, Germany.
Neurology. 2010 Nov 9;75(19):1740-4. doi: 10.1212/WNL.0b013e3181fc2823.
Neuromyelitis optica (NMO) is currently considered a severe relapsing CNS demyelinating disorder that is associated with aquaporin-4 immunoglobulin G (NMO-IgG) while in earlier reports of NMO in childhood it has been described as a benign and monophasic disorder. This study was performed to analyze the prevalence and the clinical course of NMO in a European pediatric cohort of patients with demyelinating CNS disorders.
A cohort study was performed evaluating 118 pediatric patients presenting at the Center for Multiple Sclerosis in Childhood and Adolescents, Göttingen, Germany, with demyelinating CNS disorders between 2000 and 2009. In all patients, NMO-IgG status was determined.
The majority of patients (94%) were diagnosed with remitting recurrent multiple sclerosis. Six patients fulfilled the clinical criteria for NMO but only 1 was seropositive for NMO-IgG. This patient had a severe relapsing course in contrast to the seronegative patients who showed a mild and in the majority of cases monophasic course.
The diagnostic criteria clearly distinguished the patients with NMO from patients with other demyelinating CNS disorders. In the European pediatric population, NMO is very rare and in the majority of patients not associated with NMO-IgG. These seronegative cases have a benign and predominantly monophasic course and therefore do not need the immunosuppressant therapy that is recommended for NMO in the recent literature.
视神经脊髓炎(NMO)目前被认为是一种严重的复发性中枢神经系统脱髓鞘疾病,与水通道蛋白-4 免疫球蛋白 G(NMO-IgG)相关,而在儿童时期 NMO 的早期报告中,它被描述为良性和单相疾病。本研究旨在分析欧洲儿科脱髓鞘性中枢神经系统疾病患者队列中 NMO 的患病率和临床病程。
进行了一项队列研究,评估了 2000 年至 2009 年间在德国哥廷根儿童多发性硬化中心就诊的 118 例脱髓鞘性中枢神经系统疾病的儿科患者。在所有患者中,均确定了 NMO-IgG 状态。
大多数患者(94%)被诊断为缓解复发多发性硬化症。6 名患者符合 NMO 的临床标准,但只有 1 名患者 NMO-IgG 呈阳性。与 NMO-IgG 阴性患者相比,这名患者表现出严重的复发性病程,而 NMO-IgG 阴性患者表现出轻度且多数情况下为单相病程。
诊断标准明确区分了 NMO 患者与其他脱髓鞘性中枢神经系统疾病患者。在欧洲儿科人群中,NMO 非常罕见,且在大多数患者中不与 NMO-IgG 相关。这些 NMO-IgG 阴性病例具有良性且主要为单相病程,因此不需要最近文献中推荐的 NMO 免疫抑制治疗。